The Ca-ATPase is an integral membrane enzyme which translocates two calcium ions from the cytoplasm of the cell to the sarcoplasmic reticulum lumen utilizing ATP breakdown as its energy source, in order to promote muscle relaxation. The focus of this research is the cardiac isoform of the Ca-ATPase which undergoes allosteric regulation by the phosphoprotein phospholamban (PLN). The Ca-ATPase is thought to be a target for nitrative stress and is affected by several chronic diseases of the heart. In the heart, age-based nitration of the Ca-ATPase inhibits Ca²⁺ transport activity but the physical mechanism by which nitration inhibits Ca-ATPase activity is not understood. Conversely, nitroxyl (HNO), a new candidate for drug therapy for congestive heart failure (CHF), improves overall cardiovascular function by increasing Ca-ATPase activity in the heart. However, the physical mechanism for this activation is unknown. Therefore, we have used enzyme kinetics, fluorescence spectroscopy, and EPR spectroscopy studies to determine the effects of ONOO⁻ and HNO on the Ca-ATPase and the physical regulation of the Ca-ATPase by PLN. Treatment of Ca-ATPase with a nitrating agent, ONOO⁻, inhibited Ca-ATPase activity, and the [ONOO⁻]-dependent inhibition of the Ca-ATPase was more effective in the presence of PLN. ONOO⁻ did not affect the [Ca²]-dependence of Ca-ATPase activity either in the presence or absence of PLN. ONOO⁻ had no effect on Ca-ATPase rotational mobility or oligomeric interactions, as affected by PLN, but ONOO⁻ decreased the amplitude of the Ca²⁺-dependent E2 to E1•Ca2 conformational change, both in the absence and presence of PLN. Treatment with HNO had no affect on the [Ca²⁺]-dependence of Ca-ATPase activity in the absence of PLN; however in the presence of PLN, the [Ca²⁺]-dependent activity was shifted to lower Ca²⁺ levels and corresponded to the uncoupling of PLN from the Ca-ATPase. HNO decreased Ca-ATPase rotational mobility and increased the Ca-ATPase Ca²⁺-dependent conformational transition, consistent with uncoupling PLN from the Ca-ATPase. Taken together, these results suggest that ONOO⁻ inactivates a fraction of enzyme units to lower overall enzyme activity, whereas HNO uncouples PLN from the Ca-ATPase with increases in Ca-ATPase conformational flexibility and Ca-ATPase activity. / Ph. D.

Indiana University-Purdue University Indianapolis (IUPUI) / The Ca2+ pump or Ca2+-ATPase of cardiac sarcoplasmic reticulum, SERCA2a, is regulated by phospholamban (PLB), a small inhibitory phosphoprotein that decreases the apparent Ca2+ affinity of the enzyme. We propose that PLB decreases Ca2+ affinity by stabilizing the Ca2+-free, E2·ATP state of the enzyme, thus blocking the transition to E1, the high Ca2+ affinity state required for Ca2+ binding and ATP hydrolysis. The purpose of this dissertation research is to critically evaluate this idea using series of cross-linkable PLB mutants of increasing inhibitory strength (N30C-PLB < PLB3 < PLB4). Three hypotheses were tested; each specifically designed to address a fundamental point in the mechanism of PLB action. Hypothesis 1: SERCA2a with PLB bound is catalytically inactive. The catalytic activity of SERCA2a irreversibly cross-linked to PLB (PLB/SER) was assessed. Ca2+-ATPase activity, and formation of the phosphorylated intermediates were all completely inhibited. Thus, PLB/SER is entirely catalytically inactive. Hypothesis 2: PLB decreases the Ca2+ affinity of SERCA2a by competing with Ca2+ for binding to SERCA2a. The functional effects of N30C-PLB, PLB3, and PLB4 on Ca2+-ATPase activity and phosphoenzyme formation were measured, and correlated with their binding interactions with SERCA2a measured by chemical cross-linking. Successively higher Ca2+ concentrations were required to both activate the enzyme co-expressed with N30C-PLB, PLB3, and PLB4 and to dissociate N30C-PLB, PLB3, and PLB4 from SERCA2a, suggesting competition between PLB and Ca2+ for binding to SERCA2a. This was confirmed with the Ca2+ pump mutant, D351A, which is catalytically inactive but retains strong Ca2+ binding. Increasingly higher Ca2+ concentrations were also required to dissociate N30C-PLB, PLB3, and PLB4 from D351A, demonstrating directly that PLB competes with Ca2+ for binding to the Ca2+ pump. Hypothesis 3: PLB binds exclusively to the Ca2+-free E2 state with bound nucleotide (E2·ATP). Thapsigargin, vanadate, and nucleotide effects on PLB cross-linking to SERCA2a were determined. All three PLB mutants bound preferentially to E2 state with bound nucleotide (E2·ATP), and not at all to the thapsigargin or vanadate bound states. We conclude that PLB inhibits SERCA2a activity by stabilizing a unique E2·ATP conformation that cannot bind Ca2+.

No description available.